Donor pretreatment with G-CSF reduces the severity of GVHD in a dose-dependent fashion. (A) Survival was determined by Kaplan-Meier analysis. Donor B6 mice were treated for 6 days with human G-CSF (0.2 μg/animal/d, 2 μg/animal/d, or 10 μg/animal/d) or control diluent. Splenocytes were harvested on day 7 and transplanted into lethally irradiated (1100 cGy) B6D2F1 recipient mice; T-cell dose was equilibrated across all groups (3 × 106 T cells/recipient); (control syngeneic recipients, n = 6; control allogeneic, n = 6; G-CSF 0.2 μg/d, n = 12; G-CSF 2.0 μg/d, n = 18; G-CSF 10 μg/d, n = 6). P = .03, 0.2 μg G-CSF versus 2 μg G-CSF; P = .004, 0.2 μg G-CSF versus 10 μg G-CSF. Combined results from 2 identical experiments are shown. (B) Survival was determined by Kaplan-Meier analysis. Donor B6 mice were treated with murine G-CSF (02. μg/animal/d; 0.5 μg/animal/d; or 2 μg/animal/d, for 6 days) or control diluent and transplanted as described earlier. B6D2F1 recipient mice received transplants as described earlier (control syngeneic recipients, n = 6; control allogeneic, n = 6; murine G-CSF 0.2 μg/d, n=6; murine G-CSF 2 μg/d, n=12). Survival P = .003, 0.2 μg murine G-CSF versus 2 μg murine G-CSF. Combined results from 2 identical experiments are shown.
